The Itovebi-based regimen has shown a significant reduction in the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer. This represents a statistically significant and clinically meaningful improvement in overall survival for people with this type of breast cancer. The results are being presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in the New England Journal of Medicine. The PIK3CA mutation is found in approximately 40% of HR-positive advanced breast cancers and is associated with a poor prognosis. The Itovebi-based regimen demonstrated a meaningful overall survival benefit compared with palbociclib and fulvestrant alone, with a median overall survival of 34 months. The regimen also led to a statistically significant improvement in objective response rate and delayed time to chemotherapy by approximately two years. No new safety signals were observed, with a low discontinuation due to adverse events supporting good tolerability. The Itovebi-based regimen is approved in several countries, including the United States, Switzerland, and Canada, and has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. Itovebi is currently being investigated in three additional company-sponsored phase III clinical studies in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations. The study results give confidence that the Itovebi-based regimen could become the new standard of care in the first-line setting, having demonstrated a substantial benefit on patient outcomes and quality of life. Overall, the Itovebi-based regimen has shown promising results in treating PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, and further research is being conducted to explore its potential in other breast cancer subtypes.